No description available.

Previous studies have demonstrated that the interaction of CD40 on monocytes with CD40 ligand, present on activated CD4+ T cells, induces monocyte inflammatory cytokine synthesis and rescues monocytes from apoptosis. These findings suggest a role for CD40 signaling of monocyte activation in the maintenance and/or exacerbation of nonseptic (e.g., autoimmune) inflammatory responses. In the present study the effects of the modulatory cytokines IL-4 and IL-10 on CD40-mediated signaling of monocyte IL-1beta synthesis and rescue from apoptosis were examined. Both IL-4 and IL-10 decreased CD40-dependent IL-1beta synthesis in a dose-dependent manner individually and synergized in this effect when used concurrently, with minimal effect on CD40 surface expression. CD40 signaling of IL-1beta synthesis was shown to be dependent on the induction of protein tyrosine kinase (PTK) activity, and both IL-4 and IL-10 diminished CD40-mediated tyrosine phosphorylation of monocyte cellular proteins. However, IL-4, but not IL-10, blocked CD40-mediated rescue from apoptosis, an event that we have demonstrated previously to be dependent on PTK activity as well. Together these results suggest that in monocytes 1) both IL-4 and IL-10 target CD40-induced PTK activity in the down-regulation of IL-1beta synthesis; and 2) IL-4 and IL-10 have divergent effects on the CD40 signaling pathway, in that these cytokines are synergistic with respect to their abilities to inhibit CD40-mediated IL-1beta synthesis and differ in their abilities to block CD40-mediated rescue from apoptosis.

La technologie des biopuces à ADN est un outil puissant permettant d'étudier en profondeur le profil transcriptomique d'une population cellulaire donnée. Nous avons mis à profit cette technique pour étudier les changements induits par le VIH-1 chez divers types cellulaires du système immunitaire. Notamment, nous avons déterminé l'influence du VIH-1 sur une population hautement enrichie en lymphocytes T CD4+. Cette étude nous a permis d'identifier des modulations transcriptionnelles dans plusieurs voies cellulaires importantes, dont l'apoptose, le cycle cellulaire, le métabolisme de l'ARN et la réparation du dommage à l'ADN. Nous nous sommes attardés sur la modulation de p53 au niveau de l'ARNm; nous démontrons que cette induction est dépendante d'une réponse interferon de type I. En cours de route, nous avons réalisé que le taux d'infection par le VIH-1 chez les cellules primaires était très faible - les changements décrits ci-haut sont donc susceptibles de survenir dans la population exposée au virus mais non-infectée. Afin de mieux comprendre les facteurs qui influencent l'infection au VIH-1 et les effets de celle-ci sur le transcriptome des cellules infectées, nous avons construit un virus rapporteur permettant l'isolation de cellules infectées. Nous avons utilisé ce virus pour quantifier le profil transcriptomique de lymphocytes T CD4+ infectés à l'aide de puces à ADN de dernière génération. Ces puces contiennent des sondes dirigées vers chaque exon connu, ce qui permet de détecter des changements au niveau de l'épissage alternatif en plus de l'expression génique. Les résultats démontrent qu'une sous-population de lymphocytes est particulièrement susceptible à l'infection. Finalement, nous avons procédé à la quantification transcriptomique à grande échelle des changements induits par un virus portant CD40L à sa surface sur une population de cellules B. Nous démontrons que ce virus est présent dans le plasma de patients infectés et est suffisant pour activer les lymphocytes B de façon polyclonale, ce qui pourrait expliquer en partie les déficiences observées chez ce type cellulaire chez les patients infectés au VIH-1.

Le CD154 est une glycoprotéine transmembranaire de type II, appartenant à la famille des facteurs de nécrose tumorale (TNF) et s’exprime d’une façon transitoire à la surface des lymphocytes T activés et des plaquettes. Notre laboratoire a démontré que la forme membranaire devient soluble suite à un clivage enzymatique par les métalloprotéinases (ADAM-10 et ADAM-17). De plus, il a été montré que le CD154 soluble (sCD154) peut aussi être relâché du milieu intracellulaire sans qu’il soit exprimé à la surface cellulaire suite à un clivage enzymatique intracellulaire entre les résidus acide Glutamique 112 (E112) et Méthionine 113 (M113). Les deux formes du CD154, soluble et membranaire, possèdent une structure trimérique nécessaire pour son activité biologique. Son récepteur principal, le CD40, est une glycoprotéine de type I appartenant à la famille des récepteurs des TNFs. Il est exprimé constitutivement à la surface des cellules B, des cellules dendritiques, des macrophages, des basophiles, des plaquettes, ainsi qu’à la surface de certaines cellules non hématopoïétiques telles que les cellules endothéliales, les fibroblastes et les cellules du muscle lisse vasculaire. Outre le CD40, quatre autres récepteurs appartenant à la famille des intégrines, ont été identifiés: l’αIIbβ3, l’α5β1, l’αMβ2, l’αvβ3 et l’α4β1. Les études de notre laboratoire ont démontré que l’interaction du CD154 avec ses récepteurs induit une activation bidirectionnelle, cependant, on a observé que le clivage du CD154 de la membrane cellulaire reste une propriété privilège au CD40. Le travail illustré dans cette thèse consiste à étudier l’inhibition du clivage enzymatique du CD154 et son effet dans la régulation de la réponse immune. Les résultats générés ci-dessous montrent que le CD154 résistant au clivage est un stimulant plus important que sa forme clivable. En effet, la double mutation des résidus E112 et M113 du CD154 abolit sa libération spontanée du milieu intracellulaire ainsi que son clivage de la membrane médié par le CD40 sans affecter sa liaison à ce dernier. Ce mutant s'est avéré capable d'induire une réponse apoptotique plus importante des cellules B, des réponses prolifératives plus prononcées et déclenche la différenciation des cellules B humaines d’une manière plus significative que le CD154-WT. De plus, notre étude met en évidence le développement et la caractérisation d'un anticorps monoclonal (mAb), le Clone 8, capable d'inhiber la libération/le clivage du CD154 à partir des cellules et ainsi de le maintenir à la surface cellulaire et d'augmenter sa puissance en tant qu'activateur des réponses induites par le CD40. Le Clone 8 est capable de lier le CD154 murin et d’inhiber son clivage de la surface cellulaire de la même façon que celle étudiée dans les cellules humaines. Ces travaux vont permettre le passage de cet anticorps bloquant le clivage du CD154 au stade des essais cliniques afin de mettre en place un nouveau traitement efficace pour les maladies auto-immunes et le cancer. / CD154 is a type II transmembrane glycoprotein belonging to the tumor necrosis factor superfamily (TNF), that is transiently expressed on the surface of activated T cells and platelets. We have demonstrated that this membrane form becomes soluble following an enzymatic cleavage by metalloproteinases (ADAM-10 and ADAM-17). CD154 also exists in a soluble form originating from a direct release of an intracellular processing without being expressed on the cell surface. This fragment is the result of an intracellular enzymatic cleavage between the residues Glutamic acid at position 112 (E112) and Methionine at position 113 (M113). Both soluble and membrane-bound forms of CD154 occur as non-covalently-linked homotrimers a property conveying to CD154 its biological activity. Its main receptor, CD40, is a type I glycoprotein belonging to the TNF receptor family. It is constitutively expressed on the surface of immune and non-immune cells including B cells, dendritic cells, macrophages, basophils, endothelial cells, fibroblasts, and vascular smooth muscle cells. CD154 was also shown to bind other receptors: αIIbβ3, α5β1, αMβ2, αvβ3 and α4β1 integrin. We have shown that the interaction of CD154 with its receptors induces bidirectional activation, however, only CD40 was capable of inducing the cleavage of CD154 from T cell surface. Our results here consist in studying the inhibition of the enzymatic cleavage of CD154 and its effect in the regulation of the immune response. Our data show that the cleavage resistant CD154 is a more potent stimulant than its cleavable form. Indeed, the double mutation of residues E112 and M113 of CD154 abolishes its spontaneous release from the intracellular milieu as well as its cleavage from the membrane. This mutant was found to be able to induce a stronger apoptotic response from B cells, induce more pronounced proliferative responses and trigger human B cell differentiation in a more significant way than CD154-WT. In addition, our study highlights the development and characterization of a monoclonal antibody (mAb), Clone 8, capable of inhibiting the release/cleavage of CD154 from cells and thus maintain it on the cell surface and increase its potency as an activator of CD40-induced responses. Clone 8 binds murine CD154 and inhibit its cell surface cleavage in the same way that in human cells. This study will allow the passage of this antibody blocking the cleavage of CD154 to the stage of clinical trials to develop a novel tool to treat diseases in which CD154 is implicated.

Le CD40 est une glycoprotéine transmembranaire de type I, appartenant à la famille des TNFRs, exprimée à la surface des cellules immunitaires, hématopoïétiques, vasculaires, épithéliales, et d’autres types de cellules, y compris les cellules tumorales. Le CD40 ne possédant pas de domaine kinase, pour induire un signal il interagit directement ou indirectement avec des protéines adaptatrices telles que les TRAFs et les JAKs. L’interaction du CD40 avec son principal ligand, le CD154, joue un rôle primordial dans la régulation de la réponse immunitaire et le maintien de l’homéostasie. L’activation du CD40 à la surface des cellules B augmente leur capacité de présentation d’antigène, en plus d’induire la prolifération, la commutation isotypique et l’apoptose. Les patients souffrant de mutations au niveau du gène codant pour le CD40 ou de son ligand sont immunosupprimés et sensibles à des infections opportunistes. Des études ont montré que le CD40 comme d’autres membres de la famille des TNFRs est capable de former des homodimères. Plus récemment, on a montré que la formation du CD40 homodimère est le résultat de son engagement sur les cellules B. En plus, cette homodimérisation du CD40 est importante pour la phosphorylation de l’Akt. L’interaction CD40/CD154 peut avoir un rôle direct dans l’immunothérapie par l’induction de l’apoptose de certaines cellules cancéreuses ou un rôle indirect en activant les cellules présentatrices d’antigènes (CPA) afin d'augmenter l’efficacité de l’activation des cellules T cytotoxiques. Nos résultats montrent que l’induction de la mort cellulaire par le CD40 requiert la perméabilisation du lysosome, la libération de la cathepsine B, la présence de ROS et une interaction avec le TRAF6, cette mort cellulaire programmée est plus importante en présence de la forme monomérique du CD40, muté au niveau de la cystéine 238. Par ailleurs, l’homodimérisation du CD40 requerrait sa translocation vers les radeaux lipidiques et nécessiterait la présence des ROS. Cette homodimérisation du CD40 semble être importante pour l’activation des cellules B par le biais de l’induction de l’expression du CD23, CD69 et CD80. De plus, nos résultats montrent pour la première fois une implication du CD40 homodimère dans l’induction du CD23 par le biais du TLR4. Nos résultats soulignent l’importance du CD40 homodimère dans certaines voies de signalisation. Ainsi, ils mettent en évidence le rôle de la Cys-238 dans la coopération entre des récepteurs de la réponse immunitaire innée et adaptative. Toutes ces données permettraient une meilleure compréhension de certaines voies de signalisation impliquées dans plusieurs maladies auto-immunes et faisant objet de plusieurs essais thérapeutiques. / CD40 is a type I transmembrane glycoprotein belonging to the TNFRs family, which is expressed on the surface of immune, hematopoietic cells, vascular, epithelial, and other cell types, including a wide range of tumour cells. CD40 does not have a kinase domain. Thus, to induce a signal, CD40 interacts directly or indirectly with adapter proteins such as TRAFs and Jaks. The interaction of CD40 with its main ligand, CD154, plays an important role in regulating the immune response and homeostasis. The activation of CD40 on the surface of B cells increases its ability to promote antigen presentation, in addition to inducing proliferation, isotype switching, and apoptosis. Patients affected by mutations in the gene encoding the CD40 or its ligand are immunosuppressed and susceptible to opportunistic infections. Studies have shown that CD40, as other members of the family of TNFRs is capable of forming homodimers. More recently, it was shown that the formation of the CD40 homodimer is the result of the engagement of CD40 on B cells by CD154. In addition, the homodimerization of CD40 is important for the phosphorylation of Akt. The CD40/CD154 interaction can have a direct role in immunotherapy by inducing apoptosis of some cancer cells or an indirect role in activating antigen-presenting cells (APCs), thereby increasing the effectiveness of activation of cytotoxic T cells. Our results show that the induction of cell death by CD40 requires permeabilization of the lysosome, the release of cathepsin B, the presence of ROS and interaction with TRAF6, this programmed cell death is greater in the presence of the monomeric form of CD40, due to a mutation at the level of the cysteine 238. Moreover, the homodimerization of CD40 requires its translocation to lipid rafts and the presence of ROS. This homodimerization is necessary for the CD40 B-cell activation via the induction of expression of CD23, CD69 and CD80. In addition, our results show for the first time the involvement of the CD40 homodimer in the induction of CD23 expression via TLR4. Our results emphasize the importance of CD40 homodimer in signaling pathways and highlight the role of Cys-238 in the cooperation between receptors of the innate and adaptive immune response. All together our results will allow a better understanding of CD40 signaling pathways involved in several autoimmune diseases, which give a rise to a better therapeutic trial design.

Le CD40 est une glycoprotéine transmembranaire de type I, appartenant à la famille des TNFRs, exprimée à la surface des cellules immunitaires, hématopoïétiques, vasculaires, épithéliales, et d’autres types de cellules, y compris les cellules tumorales. Le CD40 ne possédant pas de domaine kinase, pour induire un signal il interagit directement ou indirectement avec des protéines adaptatrices telles que les TRAFs et les JAKs. L’interaction du CD40 avec son principal ligand, le CD154, joue un rôle primordial dans la régulation de la réponse immunitaire et le maintien de l’homéostasie. L’activation du CD40 à la surface des cellules B augmente leur capacité de présentation d’antigène, en plus d’induire la prolifération, la commutation isotypique et l’apoptose. Les patients souffrant de mutations au niveau du gène codant pour le CD40 ou de son ligand sont immunosupprimés et sensibles à des infections opportunistes. Des études ont montré que le CD40 comme d’autres membres de la famille des TNFRs est capable de former des homodimères. Plus récemment, on a montré que la formation du CD40 homodimère est le résultat de son engagement sur les cellules B. En plus, cette homodimérisation du CD40 est importante pour la phosphorylation de l’Akt. L’interaction CD40/CD154 peut avoir un rôle direct dans l’immunothérapie par l’induction de l’apoptose de certaines cellules cancéreuses ou un rôle indirect en activant les cellules présentatrices d’antigènes (CPA) afin d'augmenter l’efficacité de l’activation des cellules T cytotoxiques. Nos résultats montrent que l’induction de la mort cellulaire par le CD40 requiert la perméabilisation du lysosome, la libération de la cathepsine B, la présence de ROS et une interaction avec le TRAF6, cette mort cellulaire programmée est plus importante en présence de la forme monomérique du CD40, muté au niveau de la cystéine 238. Par ailleurs, l’homodimérisation du CD40 requerrait sa translocation vers les radeaux lipidiques et nécessiterait la présence des ROS. Cette homodimérisation du CD40 semble être importante pour l’activation des cellules B par le biais de l’induction de l’expression du CD23, CD69 et CD80. De plus, nos résultats montrent pour la première fois une implication du CD40 homodimère dans l’induction du CD23 par le biais du TLR4. Nos résultats soulignent l’importance du CD40 homodimère dans certaines voies de signalisation. Ainsi, ils mettent en évidence le rôle de la Cys-238 dans la coopération entre des récepteurs de la réponse immunitaire innée et adaptative. Toutes ces données permettraient une meilleure compréhension de certaines voies de signalisation impliquées dans plusieurs maladies auto-immunes et faisant objet de plusieurs essais thérapeutiques. / CD40 is a type I transmembrane glycoprotein belonging to the TNFRs family, which is expressed on the surface of immune, hematopoietic cells, vascular, epithelial, and other cell types, including a wide range of tumour cells. CD40 does not have a kinase domain. Thus, to induce a signal, CD40 interacts directly or indirectly with adapter proteins such as TRAFs and Jaks. The interaction of CD40 with its main ligand, CD154, plays an important role in regulating the immune response and homeostasis. The activation of CD40 on the surface of B cells increases its ability to promote antigen presentation, in addition to inducing proliferation, isotype switching, and apoptosis. Patients affected by mutations in the gene encoding the CD40 or its ligand are immunosuppressed and susceptible to opportunistic infections. Studies have shown that CD40, as other members of the family of TNFRs is capable of forming homodimers. More recently, it was shown that the formation of the CD40 homodimer is the result of the engagement of CD40 on B cells by CD154. In addition, the homodimerization of CD40 is important for the phosphorylation of Akt. The CD40/CD154 interaction can have a direct role in immunotherapy by inducing apoptosis of some cancer cells or an indirect role in activating antigen-presenting cells (APCs), thereby increasing the effectiveness of activation of cytotoxic T cells. Our results show that the induction of cell death by CD40 requires permeabilization of the lysosome, the release of cathepsin B, the presence of ROS and interaction with TRAF6, this programmed cell death is greater in the presence of the monomeric form of CD40, due to a mutation at the level of the cysteine 238. Moreover, the homodimerization of CD40 requires its translocation to lipid rafts and the presence of ROS. This homodimerization is necessary for the CD40 B-cell activation via the induction of expression of CD23, CD69 and CD80. In addition, our results show for the first time the involvement of the CD40 homodimer in the induction of CD23 expression via TLR4. Our results emphasize the importance of CD40 homodimer in signaling pathways and highlight the role of Cys-238 in the cooperation between receptors of the innate and adaptive immune response. All together our results will allow a better understanding of CD40 signaling pathways involved in several autoimmune diseases, which give a rise to a better therapeutic trial design.

The tumor necrosis factor (TNF) receptor-associated factors (TRAFs) were initially discovered as proteins that inducibly interact with the intracellular region of TNF receptors (TNFRs). Because the TNFRs lack intrinsic catalytic activity, the TRAFs are hypothesized to orchestrate signaling activation downstream of the TNFR superfamily, however their mechanism of activation remains unclear (Inoue et al., 2000; Bishop, 2004). Originally, the TRAFs were compared to the signal transducers and activators of transcription (STAT) protein family, due to their sequence homology, and the presence of multiple RING- and zinc-finger domains, suggesting that their function may be to regulate transcriptional activity (Rothe et al., 1994; Hu et al., 1994; Sato et al. 1995; Cheng et al., 1995). However, subsequent research focused predominantly on their cytoplasmic functions, and more recently on their function as E3 ubiquitin ligases (Pineda et al., 2007). In my research, I analyzed the subcellular localizations of the TRAFs following CD40 ligand (CD40L)-stimulation, and found that TRAF2 and 3 rapidly translocate into the nucleus of primary neurons and Neuro2a cells. Interestingly, similar analysis conducted in pre-B lymphocytes (Daudi cells) revealed a different response to CD40L-stimulation, with TRAF2 and 3 being rapidly degraded within 5-minutes of stimulation. These findings are significant because they demonstrate for the first time that the TRAFs translocate into the nucleus and suggest that they may function within the nucleus in a cell-specific manner. I next analyzed the ability of TRAF2 and 3 to bind to DNA, and found that they both bind to chromatin and the NF-kappaB consensus element in Neuro2a cells, following CD40L-stimulation. Similar analyses of the chromatin binding of TRAF2 and 3 in Daudi cells revealed that they were rapidly degraded, similar to the results from my analysis of their subcellular localization. These findings show for the first time that the TRAFs interact with DNA, and therefore support the hypothesis that the TRAFs may function within the nucleus as transcriptional regulators. Finally, I analyzed the ability of the TRAFs to regulate transcriptional activity by luciferase assay. Previous studies showed that overexpression of TRAF2 and 6 could induce NF-kappaB transcriptional activity; however researchers have not been able to determine the mechanism by which they do so. In my studies, I found that every TRAF can directly regulate transcriptional activity either as co-activators or co-repressors of transcription, in a cell- and target protein-specific manner. Additionally, I found that TRAF2 can act as a transcriptional activator, and that its ability to regulate transcription is largely dependent upon the presence of its RING-finger domain. In conclusion, these studies have revealed an entirely novel function for the TRAFs as immediate-early transcriptional regulators. Future research into the genes that are regulated by the specific TRAF complexes will further elucidate how the TRAFs regulate TNFR signaling, as well as whether dysfunctions in TRAF signaling may be associated with known disorders. If specific TRAF complexes are found to regulate specific genes, then pharmacological targeting of the individual TRAF complexes may allow for the highly specific inhibition of signaling events downstream of the TNFRs, without compromising overall receptor signaling, transcription factor pathways, or cellular systems.

The NOD mouse is a widely studied model of type 1 diabetes. The loss of self-tolerance leading to autoimmune diabetes in NOD mice involves at least 27 genetic loci. Curing type I diabetes in mice and humans by islet transplantation requires overcoming both allorejection and recurrent autoimmunity. This has been achieved with systemic immunosuppression, but tolerance induction would be preferable. In addition to their genetic defects in self-tolerance, NOD mice resist peripheral transplantation tolerance induced by costimulation blockade using donor-specific transfusion and anti-CDl54 antibody. Failure has been attributed to the underlying autoimmunity, assuming that autoimmunity and resistance to transplantation tolerance have a common basis. Hypothesizing that these two abnormalities might be related, we investigated whether they had a common genetic basis. Diabetes-resistant NOD and C57BL/6 stocks congenic for various reciprocally introduced Idd loci were assessed for their ability to be tolerized. Surprisingly, in NOD congenic mice that are almost completely protected from diabetes, costimulation blockade failed to prolong skin allograft survival. In reciprocal C57BL/6 congenic mice with NOD-derived Idd loci, skin allograft survival was readily prolonged by costimulation blockade. Unexpectedly, we observed that (NOD x C57BL/6)F1 mice, which have no diabetes, nonetheless resist induction of tolerance to skin allografts. Further analyses revealed that the F1 mice shared the dendritic cell maturation defects and abnormal CD4+ T cell responses of the NOD but had lost its defects in macrophage maturation and NK cell activity. Finally, using a genome wide scan approach, we have identified four suggestive markers in the mouse genome that control the survival of skin allografts following DST and anti-CD154 mAb therapy. We suggest that mechanisms controlling autoimmunity and transplantation tolerance in NOD mice are not completely overlapping and are potentially distinct, or that the genetic threshold for normalizing the transplantation tolerance defect is higher than that for preventing autoimmune diabetes. We conclude that resistance to allograft tolerance induction in the NOD mouse is not a direct consequence of overt autoimmunity and that autoimmunity and resistance to costimulation blockade-induced transplantation tolerance phenotypes in NOD mice are not under identical genetic control.

Murine infection by the Lyme disease spirochete, B. burgdorferi, results in the generation of pathogen-specific antibody that can provide protection against Lyme disease, but the cells involved in this response are poorly characterized. T cells are not required for generating a protective antibody response to B. burgdorferi infection, but their exact role in providing protection against tissue colonization had not been previously determined. We found that TCRβxδ;-/- mice were susceptible to high pathogen loads and decreased antibody titers, but inhibition of CD40L-dependent interactions resulted in partial protection suggesting that a portion of the help provided by T cells was not dependent on CD40L-CD40 interactions between T and B cells. RAG1-/- mice reconstituted with either un-fractionated or B1-enriched peritoneal cells from previously infected mice generated B. burgdorferi-specific antibody, and upon spirochetal challenge suffered significantly lower levels of pathogen load in the joint and heart. Peritoneal cells from previously infected TCRβxδ-/- mice or B2-enriched or B1-purified peritoneal cells conferred little to only moderate protection, suggesting T cells play an important role in protection against spirochetal infection the joint. Consistent with this, T cells from previously infected donor mice, when transferred with B1 or B2 cells into RAG1-/- mice, generated increased antibody titers and were capable of diminishing bacterial burden in the joint and heart. A previously identified class of protective antibody is directed against the spirochetal surface lipoprotein DbpA, and we found that DbpA is a prominent protein antigen recognized by RAG1-/- mice reconstituted with B1-enriched peritoneal cells. Additionally, we found that mice reconstituted with B1 cells also make antibody directed towards the spirochetal glycolipid antigen, BbGL-IIc, which is recognized by Vα14iNKT cells. Consistent with the idea that T cells are important in providing protection against spirochetal infection, RAG1-/- mice reconstituted with B1 and T cells generated a more robust response against DbpA and BbGL-IIc. These results support the hypothesis that T cells act with B1 cells in a CD40L-independent manner to promote the production of antibodies that play an important role in protection of the joint from spirochetal infection.